Ga]PSMA-HBED-CC scans (0.52). SUVs relative to gluteal muscles did not differ between the two tracers. Average lesional SUVs did not differ between tracers.
Conclusion
No difference of average bone signal intensity was observed for [ [5] and bone uptake has been traditionally used by other investigators as a measure of defluorination [6] [7] [8] . In turn, free trivalent 68 Ga that has dissolved from the chelating agent, might also have a high binding affinity to osseous structures, however this would require a state of occupied binding sites on plasma proteins or very low plasma transferrin levels [9] . In this study, we systematically compared the physiological tracer uptake in bone tissue in patients without osseous metastases who underwent both [ 68 G]aPSMA-HBED-CC and [
18 F]DCFPyL PET/CT using EBONI, a software tool to automatically quantify PET tracer uptake in bone tissue, published recently by us [10] . Ga]PSMA-HBED-CC PET scan in patients with biochemical recurrence) as published previously [2, 3] . All PET/CT scans were performed on a Siemens Biograph mCT scanner (mCT 128 Flow Edge, Siemens, Knoxville, USA). PET/CT imaging was performed in accordance with the Institutional Review Board. Written informed consent was obtained from all individual participants included in the study. No change in therapeutic regimen had taken place between both scans. Acquisition and reconstruction (OSEM: 4 iterations, 12 subsets) was performed according to a protocol published previously [2] . In short, PET acquisition began 125 (+/-12) minutes after injection of 311 (+/-61) MBq [ The absence of bone metastases in 17 patients was confirmed by two experienced nuclear medicine physicians (PT, JH). Average standardized uptake value (SUV) in bone tissue (SUV-published, this software calculates tracer uptake selectively within bone tissue as defined by CT information based on Hounsfield-density [10] . The algorithmic function of EBONI is depicted in Fig 1. To avoid artefacts caused by spillover from unspecific uptake in extraosseous tissue, i.e. in facial bones due to uptake in the lacrimal and salivary glands [11] , PET/CT datasets were analyzed starting from the upper thorax downwards. Average SUV in volumes of interest (VOIs) in the homogenous liver tissue (SUV liver ) as well as in the musculus gluteus maximus (SUV gluteus ) were extracted with VINCI (http://vinci.sf.mpg.de) [12] . VOIs were drawn 68 manually so that they did not contain regions with elevated tracer uptake suspicious of being a metastasis. Minimum VOI volume was 5 ml. Exemplary VOIs are shown in Fig 2. Ratios between SUV bone and individual SUV Liver and SUV gluteus were calculated. In the bone positive group, SUV max and SUV mean of the osseous metastases were determined by semiautomatic lesion segmentation in Siemens syngo.via (Lesion threshold 40% of SUV max ). Results were checked for normal distribution with Kolmogorov-Smirnov test and compared with Wilcoxon signed rank test. P values below 0.05 were considered significant. Fig 1 illustrates the algorithmic functionality of the creation of the bone-VOI with EBONI. Since we wanted to analyze tracer uptake in patients with no bone metastases, the CT-derived bone-VOI was applied without an SUV-threshold in step 4.
Methods

Compliance with ethical standards
Results
Quantitative results with average SUV-values in the bone negative group are listed in Table 1 Ga]PSMA-HBED-CC in bone tissue (unaffected by metastases of prostate cancer) is comparable between tracers. Our data leads to the conclusion, that, for these PSMA-tracers, chemically unbound radionuclides apparently only occur in quantities that are small enough not to affect the intensity of the background signal in bone tissue. To date, both tracer families are considered widely interchangeable for most clinical applications [13] , while there is evidence that the average SUV of PSMA positive lesions is higher for [ Ga]PSMA-HBED-CC (when acquired according to the mentioned procotcols), as reported earlier by our group [2] . Here, we could not confirm a significant difference of lesional SUVs between the tracers, however, we attribute this fact to the small number of bone-positive patients we had available to include in this study. It needs to be taken into account that the imaging protocols were not entirely comparable for the two tracers. Although the same scanner was used for acquisition of all images, as compared to [ ]DCFPyL tracer's higher half-life and production yield enable this approach, which has been chosen because a better lesion contrast and resulting higher sensitivity can be expected [2, 3] .
We believe that these differences in the acquisition protocols should not have considerably affected the results of this study. First, it appears reasonable to compare the two tracers according to the usual conditions of their use in everyday practice. Second, we would not expect that later image acquisition or injection of higher tracer doses would lead to a decrease in relative bone uptake of the tracer.
The level of skeletal binding depends on the radiochemical purity achieved during tracer production. In our sample, the radiochemical purities of both tracers did not differ significantly. This further stresses the understanding that skeletal signal is only marginally affected by unbound 18 F-flouride and does not lead to differences in image quality. In addition to this observation, considering the typical biological distribution of free Gallium, an affection of the bone signal due to unspecific accumulation of the nuclide released from [ 68 Ga]PSMA-H-BED-CC could only be expected, if the Gallium binding sites of peripheral plasma proteins were occupied or plasma protein concentrations were unusually low. Therefore, under normal circumstances, an in influence of free 68 Ga could only be expected if it was administered in amounts that are several orders of magnitude higher than those typically administered in human PET examinations [9] .
The aforementioned advantages of [ 
